Utilizing induced pluripotent stem cells to study the role of alveolar type 2 cell dysfunction in pulmonary fibrosis

利用诱导多能干细胞研究肺泡2型细胞功能障碍在肺纤维化中的作用

基本信息

项目摘要

Project Summary This proposal details a 5-year career development training program focused on developing a patient-specific induced pluripotent stem cell (iPSC) model system to study the role of alveolar epithelial type 2 (AT2) cell dysfunction at the inception of pulmonary fibrosis (PF). A growing literature now implicates alveolar epithelial dysfunction as playing a role in the events that lead to downstream fibroblast activation culminating in relentless fibrosis in a variety of interstitial lung disease (ILD) syndromes, including adult idiopathic PF (IPF) and childhood ILD (chILD). However, without access to patient-specific human epithelial-mesenchymal model systems, there are limited options for testing hypotheses of how AT2 cell dysfunction leads to disease in humans. The outlined proposal builds on an in vitro human model system recently developed and published by the candidate to better understand the mechanisms by which AT2 cell dysfunction in the context of the most common disease- associated SFTPC variant (SFTPCI73T) leads to PF. The mechanisms identified by studying AT2 cell dysfunction using the in vitro iPSC-derived model will be further validated in vivo in SftpcI73T mutant mice. More specifically, the aims of this proposal are to: 1) study the role of AT2 cell dysfunction and the downstream consequences of epithelial dysfunction in eliciting a fibrotic cascade by utilizing a novel human patient-specific iPSC in vitro epithelial-mesenchymal recombinant model system, 2) test the hypothesis that AT2 cell-intrinsic perturbations characterized by proteostasis defects and metabolic reprograming result in impaired AT2-to-AT1 cell differentiation, inflammatory activation, and fibrogenic mesenchymal activation, and 3) identify druggable pathways for novel PF therapies by testing novel approaches to restore AT2 cell proteostasis and mitochondrial function. Both the model system to be developed and the pathogenic mechanisms to be revealed likely will be generalizable to a broad diversity of PF phenotypes, providing novel druggable targets for both familial and sporadic PF therapies. Dr. Alysandratos has 80% protected time from the Division of Pulmonary, Allergy, Sleep & Critical Care Medicine and the Boston University Department of Medicine. His mentor, Dr. Darrell Kotton at the Center for Regenerative Medicine (CReM), is an international expert in stem cell biology with a focus on applying stem cells to model and understand lung development and disease, making him ideally suited for this career development award focused on iPSC-model systems of PF. A team of extraordinary scientific advisory members, each bringing their specific expertise, has been carefully assembled to provide complementary guidance. A detailed training plan is presented that includes mentored research, didactic coursework, presentations at meetings, and a timeline for completion of the research aims, preparation of manuscripts, and future R01 application. At the completion of this proposal, the candidate will have developed the necessary expertise to successfully transition into an independent physician-scientist.
项目摘要 这份提案详细介绍了一项为期5年的职业发展培训计划,重点是开发针对患者的 诱导多能干细胞(IPSC)模型系统研究肺泡上皮2型(AT2)细胞的作用 肺纤维化(PF)开始时的功能障碍。现在越来越多的文献表明肺泡上皮细胞 功能障碍在导致下游成纤维细胞激活的事件中发挥作用,最终导致无情 各种间质性肺疾病(ILD)综合征的纤维化,包括成人特发性肺纤维化(IPF)和儿童 ILD(儿童)。然而,由于无法访问特定于患者的人类上皮-间充质模型系统, 测试AT2细胞功能障碍如何导致人类疾病的假设的选择有限。概述 提案建立在候选人最近开发和发表的体外人体模型系统的基础上,以更好地 了解AT2细胞功能障碍在最常见疾病背景下的机制- 相关的SFTPC变异体(SFTPCI73T)导致PF。AT2细胞功能障碍研究确定的机制 使用体外IPSC衍生模型将在SftpcI73T突变小鼠体内进一步验证。更确切地说, 这项建议的目的是:1)研究AT2细胞功能障碍的作用及其下游后果 利用一种新的人患者特异性IPSC在体外诱导纤维化级联反应中的上皮功能障碍 上皮-间充质重组模型系统,2)检验AT2细胞内源性扰动假说 以蛋白平衡缺陷和代谢重编程为特征的AT2-to-AT1细胞受损 分化、炎症激活和纤维化间质激活,以及3)确定可用药 通过测试恢复AT2细胞蛋白平衡和线粒体的新方法为PF治疗提供新途径 功能。无论是要开发的模型系统,还是要揭示的致病机制都可能是 可推广到广泛多样化的Pf表型,为家族和 零星的PF疗法。AlySandratos博士有80%的保护时间来自肺,过敏,睡眠部门 和重症护理医学和波士顿大学医学部。他的导师,达雷尔·科顿博士 再生医学中心(CReM)是干细胞生物学的国际专家,专注于 应用干细胞来建模和了解肺发育和疾病,使他成为这方面的理想人选 职业发展奖聚焦于PF的IPSC模式系统。一支非凡的科学顾问团队 每个成员都带来了各自的专业知识,经过精心组装,以提供互补的 指导。提出了详细的培训计划,包括有指导的研究、授课课程、 在会议上的陈述,以及完成研究目标、准备手稿的时间表,以及 未来的R01应用。在完成这项建议时,候选人将制定出必要的 成功转型为独立内科医生-科学家的专业知识。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Konstantinos Alysandratos其他文献

Konstantinos Alysandratos的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Gain-of-function toxicity in alpha-1 antitrypsin deficient type 2 alveolar epithelial cells
α-1 抗胰蛋白酶缺陷型 2 型肺泡上皮细胞的功能获得毒性
  • 批准号:
    10751760
  • 财政年份:
    2024
  • 资助金额:
    $ 16.22万
  • 项目类别:
The role of alveolar macrophages and regulatory pathways in post-transplant lung inflammation.
肺泡巨噬细胞和调节途径在移植后肺部炎症中的作用。
  • 批准号:
    23K08315
  • 财政年份:
    2023
  • 资助金额:
    $ 16.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanical signaling through the nuclear membrane in lung alveolar health
通过核膜的机械信号传导影响肺泡健康
  • 批准号:
    10677169
  • 财政年份:
    2023
  • 资助金额:
    $ 16.22万
  • 项目类别:
Mechanistic studies of the genetic contribution of desmoplakin to pulmonary fibrosis in alveolar type 2 cells
桥粒斑蛋白对肺泡2型细胞肺纤维化的遗传贡献机制研究
  • 批准号:
    10736228
  • 财政年份:
    2023
  • 资助金额:
    $ 16.22万
  • 项目类别:
Pilot Studies of PAX3-FOXO1 Fusions Proteins in Alveolar Rhabdomyosarcoma
PAX3-FOXO1 融合蛋白在肺泡横纹肌肉瘤中的初步研究
  • 批准号:
    10726763
  • 财政年份:
    2023
  • 资助金额:
    $ 16.22万
  • 项目类别:
Novel alveolar mechanisms of hypoxemia in hepatopulmonary syndrome
肝肺综合征低氧血症的新肺泡机制
  • 批准号:
    10718446
  • 财政年份:
    2023
  • 资助金额:
    $ 16.22万
  • 项目类别:
Injury of blood brain and alveolar-endothelial barriers caused by alcohol and electronic cigarettes via purinergic receptor signaling
酒精和电子烟通过嘌呤受体信号传导引起血脑和肺泡内皮屏障损伤
  • 批准号:
    10638221
  • 财政年份:
    2023
  • 资助金额:
    $ 16.22万
  • 项目类别:
Alveolar Epithelial Cell Dysfunction Induced By Flavored E-Cigarette Aerosols
加味电子烟气雾剂引起的肺泡上皮细胞功能障碍
  • 批准号:
    10770080
  • 财政年份:
    2023
  • 资助金额:
    $ 16.22万
  • 项目类别:
Delineating the role of let-7 microRNA on lung AT2 cell homeostasis, alveolar regeneration, and interstitial lung disease
描述let-7 microRNA对肺AT2细胞稳态、肺泡再生和间质性肺疾病的作用
  • 批准号:
    10634881
  • 财政年份:
    2023
  • 资助金额:
    $ 16.22万
  • 项目类别:
Alveolar Dead Space and New or Progressive MODS
肺泡死腔和新的或进展性 MODS
  • 批准号:
    10740810
  • 财政年份:
    2023
  • 资助金额:
    $ 16.22万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了